CYP2C19 intermediate and poor metabolizer statuses may be associated with coronary atherosclerosis among patients with type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) has a higher risk of coronary atherosclerosis (CAS) compared to the general population. Cytochrome P450 2C19 (CYP2C19) closely related to the occurrence and development of cardiovascular diseases. This study intends to conduct research on the relationship between <i>CYP2C19</i> polymorphisms ((rs4244285, 681G > A, *2) and (rs4986893, 636G > A, *3)) and the risk of CAS in patients with T2DM. 4,627 T2DM patients from January 2019 to March 2024 were retrospectively analyzed, included 2,390 cases of T2DM complicated with CAS and 2,237 cases of patients with T2DM only. CYP2C19 was divided into three phenotypes: extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) based on rs4244285 and rs4986893 SNPs. The relationship between <i>CYP2C19</i> polymorphisms and CAS risk was analyzed. There were 1,403(30.3%) patients with dyslipidemia, and dyslipidemia (41.1% vs. 18.8%, <i>p</i> < 0.001) in patients with CAS was higher than those in controls. The frequencies of <i>CYP2C19</i> IM and PM phenotypes in CAS patients were higher than those in controls. Logistic regression analysis showed that advanced age (odds ratio (OR): 1.273, 95% confidence interval (CI): 1.099-1.473, <i>p</i> = 0.001), overweight (OR: 1.175, 95% CI: 1.039-1.328, <i>p</i> = 0.010), smoking (OR: 1.238, 95% CI: 1.049-1.462, <i>p</i> = 0.012), alcoholism (OR: 1.445, 95% CI: 1.040-2.007, <i>p</i> = 0.028), hypertension (OR: 1.229, 95% CI: 1.047-1.442, <i>p</i> = 0.012), dyslipidemia (OR: 3.027, 95% CI: 2.641-3.469, <i>p</i> < 0.001), <i>CYP2C19</i> IM/PM phenotype(IM + PM vs. EM phenotype, OR: 1.290, 95% CI: 1.140-1.459, <i>p</i> < 0.001) were associated with CAS in T2DM. <i>CYP2C19</i> IM + PM phenotypes, advanced age, overweight, history of smoking, history of alcoholism, hypertension, and dyslipidemia may be associated with CAS in T2DM.